Nephros to Present at the LD Micro Main Event

LOS ANGELES, CA / ACCESSWIRE / November 24, 2015 / Nephros (OTCQB:NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters and an on-line mid-dilution hemodiafiltration system for the treatment of chronic renal failure patients, today announced that it will be presenting at the 8th annual LD Micro Main Event on Tuesday, December 1st at 3 PM PST / 6 PM EST. President and CEO and Nephros, Daron Evans, will be giving the presentation and meeting with investors.

The conference will be held at the Luxe Sunset Bel Air Hotel and will feature 210 companies in the small / micro-cap space.

About Nephros, Inc.

Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with end stage kidney disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients.

For more information about Nephros, please visit the company’s website at www.nephros.com.

About LD Micro

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Invitational in June. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com.

Contact:

Name: Kirin M. Smith, PCG Advisory Group
Phone: 646-863-6519
Email: ksmith@pcgadvisory.com

SOURCE: Nephros, Inc.

ReleaseID: 433959